Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nobelpharma Takes Nobelzin Patent Fight to IP High Court
Nobelpharma said on September 26 that it is taking Sawai Pharmaceutical to the Intellectual Property High Court in Japan over the generic major’s copycat version of the copper absorption inhibitor Nobelzin Tablets (zinc acetate hydrate). In April 2023, Nobelpharma had…
To read the full story
Related Article
- Nobelpharma Seeks Provisional Disposition against Sawai’s Nobelzin Copy
November 7, 2023
- Nobelpharma Grants Authorized Generic Rights to Japanese Firm
June 26, 2023
- Nobelpharma Sues Sawai over Nobelzin Patent in Japan
April 19, 2023
BUSINESS
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Sumitomo to Launch Post-Marketing Study for iPSC Therapy by Year-End
March 9, 2026
- Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
March 9, 2026
- Nitrosamine Detected in Nichi-Iko’s Tryptanol, No Need to Halt Prescriptions
March 9, 2026
- Towa Broadens Label for Tacrolimus in Cell Transplantation
March 9, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…